Guest guest Posted January 21, 2000 Report Share Posted January 21, 2000 Genetically Engineered Cells May Stimulate Natural Defense Against Epstein-Barr Virus (EBV) A study published in the most recent issue of the Journal of Virology describes a novel process that researchers say may help in the development of a vaccine for treatment and prevention of Epstein-Barr virus (EBV). EBV has been associated with a number of malignant conditions, especially in people with compromised immune systems. Scientist took dendritic (nerve) cells, which direct the immune response at a cellular level, and genetically modified them to react against EBV. This EBV-immune response information is then stored until needed using altered adenoviruses. These viruses that cause respiratory or eye infections are used in genetic therapy to carry specific anti-tumor genes. Scientists reported that this method was successful in stimulating EBV-specific immune-response cells in test tubes; further testing will decide the potential of this genetic technology for EBV-associated malignancies. 12-19-99 Source: Dendritic cells transduced with an adenovirus vector encoding Epstein-Barr virus latent membrane protein 2B: a new modality for vaccination. Journal of Virology 1999;73(12):10416-10425. ******************************************************** DrugDigest is the most comprehensive source of non-commercial, fact-based health and medical information on the Internet. We offer eBulletin Service on more than 25 health topics. To learn more, go to: http://www.drugdigest.org/bulletins//bulletins/index.html Quote Link to comment Share on other sites More sharing options...
Recommended Posts
Join the conversation
You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.